Mechanistic blockade of Pseudomonas aeruginosa type III secretion by a monoclonal antibody targeting the pore size-determining domain of PcrV
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00405-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Yu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Type III Secretion Systems, Antibodies, Monoclonal, Pseudomonas Infections. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pseudomonas aeruginosa bloodstream infections carry mortality rates exceeding 60%, with escalating antibiotic resistance dramatically limiting therapeutic options. The type III secretion system (T3SS), a virulence apparatus delivering cytotoxic effectors via PcrV-dependent translocation pores, represents a therapeutic target. Here, we developed a monoclonal antibody (5C8) targeting the central domain (H106-D173) of PcrV, which regulates translocation pore size. 5C8 demonstrated sub-nanomolar affinity (KD = 0.32 nM) via biolayer interferometry and broad neutralization efficacy against clinical isolates (IC 50 : 0.32–1.47 μg/mL). In murine bloodstream infection models, 5C8 conferred improved survival against cytotoxic ( exoU + ) and invasive ( exoS + ) strains ( P < 0.01 vs controls), reducing bacterial loads in lungs/kidneys by 1.5-log 10 colony-forming unit ( P < 0.01) and suppressing interleukin-6 levels by 60–82% ( P < 0.01). Mechanistic studies revealed 5C8’s dual action: blocking effector release (ExoU/ExoT reduced by 41–88% via liquid chromatography-mass spectrometry) and constricting T3SS pores below 1.2 nm (carbohydrate exclusion assay). Molecular docking identified D125/K129/Y145 as critical binding residues, validated by alanine scanning and mutant construction. Humanized Hu5C8 retained potency (KD = 0.55 nM) with extended half-life (t 1/2 = 91.26 h) through Fc receptor engineering. As an inhibitor targeting the pore size-determining domain of PcrV, 5C8 disrupts virulence through a novel dual mechanism, providing a paradigm-shifting strategy against multidrug-resistant P. aeruginosa , bridging a critical gap in sepsis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
- Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
- Starmab Biologics (Suzhou) Co., Ltd., Shanghai, China.
- Department of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Guo, S., Jiang, L., Wang, S., Hou, W., Qiu, X., Shen, H., & An, M. (2025). Mechanistic blockade of Pseudomonas aeruginosa type III secretion by a monoclonal antibody targeting the pore size-determining domain of PcrV. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00405-25
Vancouver
Zhang Y, Guo S, Jiang L, Wang S, Hou W, Qiu X, et al. Mechanistic blockade of Pseudomonas aeruginosa type III secretion by a monoclonal antibody targeting the pore size-determining domain of PcrV. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00405-25
BibTeX
@article{Zhang2025,
author = {Zhang, Yu and Guo, Shiyu and Jiang, Liwen and Wang, Siqi and Hou, Weitong and Qiu, Xiran and Shen, Hui and An, Maomao},
title = {Mechanistic blockade of Pseudomonas aeruginosa type III secretion by a monoclonal antibody targeting the pore size-determining domain of PcrV},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00405-25}
}
EUVIMED